Market closedNon-fractional

Nurix Therapeutics/NRIX

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Ticker

NRIX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Francisco, United States

Employees

284

NRIX Metrics

BasicAdvanced
$1.2B
Market cap
-
P/E ratio
-$2.65
EPS
2.06
Beta
-
Dividend rate
$1.2B
2.06
2.864
2.794
12.946
17.278
-28.80%
-65.37%
12.77
5.54
5.54
-12.31
94.02%
-24.32%
59.41%
1.17%

What the Analysts think about NRIX

Analyst Ratings

Majority rating from 12 analysts.
Buy

NRIX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-251.51% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$17M
9.27%
Net income
-$42M
-0.95%
Profit margin
-251.51%
-9.36%

NRIX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.24%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-$0.68
-$0.77
-$0.76
-
Expected
-$0.56
-$0.76
-$0.57
-$0.80
-$0.65
Surprise
-19.64%
-10.03%
35.09%
-5.24%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Nurix Therapeutics stock?

Nurix Therapeutics (NRIX) has a market cap of $1.2B as of July 05, 2024.

What is the P/E ratio for Nurix Therapeutics stock?

The price to earnings (P/E) ratio for Nurix Therapeutics (NRIX) stock is 0 as of July 05, 2024.

Does Nurix Therapeutics stock pay dividends?

No, Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Nurix Therapeutics dividend payment date?

Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders.

What is the beta indicator for Nurix Therapeutics?

Nurix Therapeutics (NRIX) has a beta rating of 2.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Nurix Therapeutics stock

Buy or sell Nurix Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing